Ravicti Mechanism of Action
Ravicti (glycerol phenylbutyrate) functions as a nitrogen-scavenging agent that provides an alternative pathway for waste nitrogen excretion in patients with urea cycle disorders by conjugating with glutamine to form phenylacetylglutamine, which is then renally excreted. 1
How It Works
Ravicti is a triglyceride prodrug containing three molecules of phenylbutyric acid (PBA) esterified to a glycerol backbone. The mechanism unfolds through the following steps:
Step 1: Intestinal Hydrolysis
Upon oral ingestion, pancreatic lipases (including triglyceride lipase, pancreatic lipase-related protein 2, and carboxyl-ester lipase) hydrolyze Ravicti in the gastrointestinal tract, releasing PBA from the glycerol backbone 1, 2.
Step 2: Conversion to Active Metabolite
The released PBA undergoes β-oxidation to form phenylacetic acid (PAA), which is the active moiety responsible for nitrogen scavenging 1.
Step 3: Glutamine Conjugation
PAA conjugates with glutamine (which contains 2 molecules of nitrogen) via acetylation in the liver and kidneys to form phenylacetylglutamine (PAGN) 1.
Step 4: Renal Excretion
PAGN is excreted by the kidneys, carrying with it 2 moles of nitrogen per mole—equivalent to urea on a molar basis—thereby providing an alternate vehicle for waste nitrogen excretion 1.
Clinical Context
This mechanism is particularly relevant in urea cycle disorders (UCDs), which are inherited deficiencies of enzymes or transporters necessary for synthesizing urea from ammonia. Without these enzymes, toxic levels of ammonia accumulate in blood and brain 1. Ravicti bypasses the defective urea cycle entirely by creating this alternative nitrogen elimination pathway 3.
Pharmacokinetic Advantage
The prodrug formulation provides delayed-release characteristics compared to sodium phenylbutyrate. Peak plasma levels of PBA, PAA, and PAGN occur at 2,4, and 4 hours respectively after single dosing, with steady-state levels at 8,12, and 10 hours after the first daily dose in patients with UCDs 1. This gradual release pattern, resulting from stepwise pancreatic lipase hydrolysis, contributes to superior ammonia control with lower peak metabolite concentrations compared to immediate-release formulations 4, 2.
Important Caveats
- Hepatic impairment may reduce conversion of PAA to PAGN, potentially leading to PAA accumulation, as this conjugation occurs in the liver 1
- Intact glycerol phenylbutyrate is not detectable in plasma of UCD patients, confirming complete hydrolysis in the GI tract 1
- The drug is classified as a nitrogen-binding agent rather than a traditional ammonia scavenger, reflecting its mechanism of binding nitrogen via glutamine conjugation 1